1. Home
  2. OBIO vs NEWT Comparison

OBIO vs NEWT Comparison

Compare OBIO & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • NEWT
  • Stock Information
  • Founded
  • OBIO 2017
  • NEWT N/A
  • Country
  • OBIO United States
  • NEWT United States
  • Employees
  • OBIO N/A
  • NEWT N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • NEWT Major Banks
  • Sector
  • OBIO Health Care
  • NEWT Finance
  • Exchange
  • OBIO Nasdaq
  • NEWT Nasdaq
  • Market Cap
  • OBIO 291.7M
  • NEWT 338.4M
  • IPO Year
  • OBIO N/A
  • NEWT N/A
  • Fundamental
  • Price
  • OBIO $8.51
  • NEWT $14.74
  • Analyst Decision
  • OBIO Strong Buy
  • NEWT Buy
  • Analyst Count
  • OBIO 2
  • NEWT 4
  • Target Price
  • OBIO $17.00
  • NEWT $14.50
  • AVG Volume (30 Days)
  • OBIO 248.5K
  • NEWT 164.3K
  • Earning Date
  • OBIO 08-08-2024
  • NEWT 08-05-2024
  • Dividend Yield
  • OBIO N/A
  • NEWT 5.17%
  • EPS Growth
  • OBIO N/A
  • NEWT 7.14
  • EPS
  • OBIO N/A
  • NEWT 1.80
  • Revenue
  • OBIO $2,216,000.00
  • NEWT $199,910,000.00
  • Revenue This Year
  • OBIO $17.90
  • NEWT $34.20
  • Revenue Next Year
  • OBIO $10.51
  • NEWT $6.03
  • P/E Ratio
  • OBIO N/A
  • NEWT $8.17
  • Revenue Growth
  • OBIO N/A
  • NEWT 59.31
  • 52 Week Low
  • OBIO $4.22
  • NEWT $10.07
  • 52 Week High
  • OBIO $11.69
  • NEWT $19.36
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 62.57
  • NEWT 72.12
  • Support Level
  • OBIO $7.48
  • NEWT $12.40
  • Resistance Level
  • OBIO $8.20
  • NEWT $12.89
  • Average True Range (ATR)
  • OBIO 0.60
  • NEWT 0.36
  • MACD
  • OBIO 0.04
  • NEWT 0.23
  • Stochastic Oscillator
  • OBIO 89.59
  • NEWT 99.29

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About NEWT NewtekOne Inc.

NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.

Share on Social Networks: